Publications
Detailed Information
Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jinyong | - |
dc.contributor.author | Chang, Euijin | - |
dc.contributor.author | Park, Song Yi | - |
dc.contributor.author | Lee, Dae-Won | - |
dc.contributor.author | Kang, Chang Kyung | - |
dc.contributor.author | Choe, Pyoeng Gyun | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Oh, Myoung-Don | - |
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.date.accessioned | 2023-03-20T08:36:16Z | - |
dc.date.available | 2023-03-20T08:36:16Z | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.created | 2022-12-27 | - |
dc.date.issued | 2022-12 | - |
dc.identifier.citation | Oncologist, Vol.27 No.12, pp.e931-e937 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.uri | https://hdl.handle.net/10371/189410 | - |
dc.description.abstract | © The Author(s) 2022. Published by Oxford University Press.BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic affected millions of individuals, and patients with cancer are known to be more susceptible. Vaccines against SARS-CoV-2 have been developed and used for patients with cancer, but scarce data are available on their efficacy in patients under active anti-cancer therapies. MATERIALS AND METHODS: In this study, we semi-quantitatively measured the titers of the immunoglobulin G against the anti-spike protein subunit 1 of SARS-CoV-2 after vaccination of patients with early breast cancer undergoing concurrent chemotherapy, endocrinal or targeted non-cytotoxic treatments, and no treatments. RESULTS: Standard doses of COVID-19 vaccines provided sufficient immune responses in patients with early breast cancer, regardless of the type of anticancer therapies. However, the post-vaccination serum anti-spike antibody titers were significantly lower in the patients under cytotoxic chemotherapy. CONCLUSION: Our study emphasizes the importance of the personalized risk stratification and consideration for booster doses in more vulnerable populations. | - |
dc.language | 영어 | - |
dc.publisher | AlphaMed Press Inc | - |
dc.title | Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment | - |
dc.type | Article | - |
dc.identifier.doi | 10.1093/oncolo/oyac196 | - |
dc.citation.journaltitle | Oncologist | - |
dc.identifier.wosid | 000865995400001 | - |
dc.identifier.scopusid | 2-s2.0-85143645504 | - |
dc.citation.endpage | e937 | - |
dc.citation.number | 12 | - |
dc.citation.startpage | e931 | - |
dc.citation.volume | 27 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Dae-Won | - |
dc.contributor.affiliatedAuthor | Kim, Nam Joong | - |
dc.contributor.affiliatedAuthor | Oh, Myoung-Don | - |
dc.contributor.affiliatedAuthor | Park, Wan Beom | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | SARS-CoV-2 vaccines | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | adjuvant chemotherapy | - |
dc.subject.keywordAuthor | anti-spike antibody | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.